Perampanel Hydrate

吡仑帕奈

Report date: 2026/02/24 20:00:16
NMEFirst In Class

Base Information

Drug NamePerampanel Hydrate
Drug Alias Nameperampanelum培雷帕奈perampanelFycompaER-15505590 +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGlutamate receptor ionotropic AMPA antagonists
TargetsGlutamate receptor ionotropic AMPA
Therapy Area/IndicationsAlcoholismHeart ArrestSmall Fiber Neuropathy +[17] 
Global Approved IndicationsSeizuresEpilepsy, Tonic-ClonicEpilepsies, Partial +[4] 
Approved Indications in ChinaEpilepsies, Partial
Original Approved Country/TerritoryEU
Original Approved Date2012/07/23
Country/TerritoryCzechiaBelgiumBulgaria +[44] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesEisai Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstituteUniversity Of California San FranciscoHumanis Saglık Anonim Sirketi +[9] 
Inactive CompaniesEisai Manufacturing LtdEisai LtdTokyo Medical University +[9] 
Active IndicationsAlcoholismHeart ArrestStatus Epilepticus +[8] 
Inactive IndicationsSmall Fiber NeuropathyNeuralgiaDiabetic Neuropathies +[9] 

Other Information

ATC CodeN03AX22
Related LinksWikipediaDrugBankKEGG